Overweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation
ABSTRACT Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a leading indication for liver transplantation (LT), but also occurs after LT. The prevalence of de novo MASLD (dnMASLD) after LT, based on both surveillance (svLbx) and indication biopsies (indLbx), is...
Uloženo v:
| Vydáno v: | Clinical transplantation Ročník 38; číslo 11; s. e70039 - n/a |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Denmark
John Wiley and Sons Inc
01.11.2024
|
| Témata: | |
| ISSN: | 0902-0063, 1399-0012, 1399-0012 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | ABSTRACT
Background and Aims
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a leading indication for liver transplantation (LT), but also occurs after LT. The prevalence of de novo MASLD (dnMASLD) after LT, based on both surveillance (svLbx) and indication biopsies (indLbx), is unknown. Furthermore, the impact of the distinct cardiometabolic risk factors on histological disease activity has not been assessed. We aimed to evaluate the prevalence of dnMASLD and the association between the cardiometabolic risk factors and histological disease activity.
Methods
We performed a retrospective single‐center study in a LT cohort with indLbx and svLbx. Patients with NAFLD before LT were excluded.
Results
We analyzed 249 patients who underwent either svLbx or indLbx. Forty‐eight (19.2%) had either dnMASLD (n = 26/249, 10.4%) or metabolic dysfunction associated steatohepatitis (dnMASH) (n = 22/249, 8.8%). Although dnMASLD/dnMASH was more frequent in indLbx (35.1%, p < 0.01), still 16.5% of patients with svLbx had dnMASLD/dnMASH. While overweight (p < 0.01) and diabetes (p = 0.01) were more frequent in patients with dnMASH, only overweight was associated with histological disease activity in the multivariate analysis. No impact of dnMASLD on the overall survival was observed.
Conclusion
While dnMASLD is more frequent in patients with indLBX, it also occurs in 16.5% of patients without signs of graft dysfunction. Overweight has the strongest impact on histological disease activity and should be monitored carefully after LT. |
|---|---|
| Bibliografie: | Katharina Hupa‐Breier and Bastian Engel were supported by the PRACTIS–Clinician Scientist Program of Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3‐1). Alejandro Campos‐Murguia is supported by the DAAD Research Grants–One‐Year Grants for Doctoral Candidates, 2023/24 (57645447). Funding Alejandro Campos‐Murguia and Lea Guetzlaff contributed equally to this study. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Funding: Katharina Hupa‐Breier and Bastian Engel were supported by the PRACTIS–Clinician Scientist Program of Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3‐1). Alejandro Campos‐Murguia is supported by the DAAD Research Grants–One‐Year Grants for Doctoral Candidates, 2023/24 (57645447). |
| ISSN: | 0902-0063 1399-0012 1399-0012 |
| DOI: | 10.1111/ctr.70039 |